XLO
Xilio Therapeutics, Inc.
There isn't enough reported data to score XLO yet.
XLO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
XLO's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
XLO PE Valuation
XLO has no meaningful PE right now: it lost money over the past year.
XLO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect XLO's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
XLO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2024 | -$24.08 | +$17.36 |
| Q2 2024 | -$29.54 | +$13.44 |
| Q1 2024 | -$35.98 | +$9.80 |
| Q4 2023 | -$38.92 | +$6.16 |
XLO is still losing money, but less than at its worst: $24.08 per share over the past year, against $45.78 at its worst in early 2023.
XLO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10M | -48% |
| Q2 2026 | $18.7M | +131% |
| Q1 2026 | $12.6M | +332% |
| Q4 2025 | $13.7M | +694% |
| Q3 2025 | $19.1M | +743% |
| Q2 2025 | $8.1M | +243% |
XLO's revenue is growing: $10M last quarter, down 48% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -118% | -108 points |
| Q2 2026 | -19% | +159 points |
| Q1 2026 | -112% | +361 points |
| Q4 2025 | -86% | +704 points |
| Q3 2025 | -10% | +642 points |
| Q2 2025 | -178% | +446 points |
| Q1 2025 | -473% | N/A |
| Q4 2024 | -791% | N/A |
XLO's operating margin was −118% last quarter, down 108 points from the same quarter a year ago.
XLO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$13.9M | +$3.6M |
| Q2 2026 | -$18.8M | -$3.9M |
| Q1 2026 | -$22.9M | -179% |
| Q4 2025 | -$2.1M | +$12.1M |
| Q3 2025 | -$17.5M | -$3.8M |
| Q4 2024 | -$14.2M | -$736K |
| Q3 2024 | -$13.7M | -$312K |
| Q4 2023 | -$13.4M | +$5.3M |
XLO has burned cash in almost every quarter: −$58M over the past year, against −$18M the year before.
XLO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.5% | +283K shares |
| 1 year | +186% | +12.8M shares |
| 3 years | +905% | +17.7M shares |
XLO has 20M diluted shares, up 186% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
XLO Net Leverage
XLO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
XLO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.6 | Neutral |
| Stochastic | 43.7 | Neutral |
XLO's weekly RSI is 45 (neutral) and its Stochastic is 44 (neutral).
XLO PE vs Healthcare Sector
XLO has no meaningful PE right now: it lost money over the past year.
XLO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.51 | 3.2% below |
| 20 week MA | $8.83 | 6.7% below |
| 50 week MA | $8.61 | 4.3% below |
| 100 week MA | $9.94 | 17% below |
| 200 week MA | $17.1 | 52% below |
XLO is in a downtrend: it's below all five of its weekly moving averages, and 52% below its 200-week average.
XLO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $224.0 | $224.0 | 0% |
| 2022 | $224.0 | $32.9 | -85% |
| 2023 | $32.9 | $7.70 | -77% |
| 2024 | $7.70 | $13.6 | +77% |
| 2025 | $13.6 | $9.27 | -32% |
| 2026 YTD | $9.27 | $8.24 | -11% |
XLO has finished lower in four of the last five years. It's down 11% so far in 2026.